GlassScriptPhysician profile
Aaron-Ross Gutierrez Jimenez
NPI 1053816157
$21,859.66
in general payments reported to CMS, 2019-2025
32 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.64 · 2022: $213 · 2023: $741 · 2024: $1,592 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $6,490 · Travel and Lodging: $2,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,546.00 |
| Food and Beverage | $6,489.51 |
| Travel and Lodging | $2,511.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15,690.55 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $1,138.67 | 2021-2025 | Korlym |
| Amgen INC. | $767.68 | 2024-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $659.33 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $296.93 | 2023-2025 | |
| Mannkind Corporation | $280.83 | 2024-2025 | |
| Medtronic, INC. | $256.22 | 2024-2025 | Minimed 780g, Inceptiv |
| Genzyme Corporation | $241.68 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $233.74 | 2023-2025 | Strensiq |
| Lilly USA, LLC | $224.46 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Xeris Pharmaceuticals, INC. | $205.51 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $185.09 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $184.29 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.12 | 2024-2025 | Jardiance |
| Almatica Pharma LLC | $153.74 | 2025 | Teriparatide |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $152.84 | 2025 | |
| Antares Pharma, INC. | $129.31 | 2024 | Xyosted |
| Madrigal Pharmaceuticals | $116.38 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $103.13 | 2024-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $91.98 | 2024-2025 | Dupixent |
| Intra-Sana Laboratories | $84.58 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ascendis Pharma Endocrinology INC | $83.36 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $73.98 | 2023-2025 | Cuvitru, Takhzyro |
| Abbott Laboratories | $72.31 | 2024-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $57.10 | 2024-2025 | Tymlos |
| Inspire Medical Systems, INC. | $49.74 | 2023 | Inspire |
| Tolmar, INC. | $43.66 | 2025 | Jatenzo |
| Kyowa Kirin, INC. | $27.95 | 2024 | Crysvita |
| Insulet Corporation | $23.39 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $23.22 | 2025 | |
| Verity Pharmaceuticals INC. | $22.30 | 2025 | Tlando |
| Cequr Corporation | $19.59 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron-Ross Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.